Nutriband Inc. (NASDAQ: NTRB), a company focused on developing transdermal pharmaceutical products, announced that its CEO and Co-Founder Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit. The presentation is scheduled as part of the CEO Spotlight event on Aug. 26, the second day of the two-day summit, which will be held at the Sandy Springs Performing Arts Centre in Sandy Springs, Georgia.
The summit, taking place Aug. 25-26, brings together leaders from the biotechnology, medical technology, research, manufacturing, and investment sectors. It serves as a platform for discussing innovations and trends that are shaping the future of life sciences. Sheridan's participation underscores Nutriband's growing prominence in the pharmaceutical industry, particularly in the development of technologies aimed at addressing the opioid crisis.
At the heart of Nutriband's efforts is AVERSA™, an abuse-deterrent transdermal technology designed to incorporate aversive agents into patches. This technology is intended to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The company's lead product under development is an abuse-deterrent fentanyl patch that utilizes AVERSA™. Fentanyl is a potent synthetic opioid that has been a major contributor to the opioid epidemic, making the development of safer delivery methods critically important.
The implications of this presentation are significant. By showcasing AVERSA™ at a major industry event, Nutriband is positioning itself as a key player in the fight against opioid misuse. The technology has the potential to revolutionize how Schedule II drugs are administered, offering a safer alternative for patients who require strong pain management while reducing the risk of diversion and abuse.
Furthermore, the presentation could attract potential partners, investors, and collaborators who are interested in supporting innovative solutions to public health challenges. The summit provides an ideal venue for Nutriband to highlight the progress of its lead product and to discuss future developments.
For more information about Nutriband and its pipeline, visit the company's website at www.nutriband.com. The latest news and updates relating to NTRB are available in the company's newsroom at https://ibn.fm/NTRB.
